Avastin 25mg/ml concentrate for solution for infusion

Avastin 

On 15 May 2013, safety information on Avastin was issued. Necrotising fasciitis, including fatal cases, has been reported in patients receiving Avastin in both clinical trials and in the post-marketing setting. It is recommended that Avastin is discontinued and appropriate therapy initiated promptly upon diagnosis of necrotising fasciitis.
Further information is available on the MHRA website.

Table of Contents

• 1. Name of the medicinal product
• 2. Qualitative and quantitative composition
• 3. Pharmaceutical form
• 4. Clinical particulars
• 4.1 Therapeutic indications
• 4.2 Posology and method of administration
• 4.3 Contraindications
• 4.4 Special warnings and precautions for use
• 4.5 Interaction with other medicinal products and other forms of interaction
• 4.6 Fertility, pregnancy and lactation
• 4.7 Effects on ability to drive and use machines
• 4.8 Undesirable effects
• 4.9 Overdose
• 5. Pharmacological properties
• 5.1 Pharmacodynamic properties
• 5.2 Pharmacokinetic properties
• 5.3 Preclinical safety data
• 6. Pharmaceutical particulars
• 6.1 List of excipients
• 6.2 Incompatibilities
• 6.3 Shelf life
• 6.4 Special precautions for storage
• 6.5 Nature and contents of container
• 6.6 Special precautions for disposal and other handling
• 7. Marketing authorisation holder
• 8. Marketing authorisation number(s)
• 9. Date of first authorisation/renewal of the authorisation
• 10. Date of revision of the text